{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:15:51Z","timestamp":1760267751939,"version":"3.37.3"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Grupo de Estudo da Doen\u00e7a Inflamat\u00f3ria Intestinal","award":["02.00280"],"award-info":[{"award-number":["02.00280"]}]},{"name":"Merck Sharp & Dohme, Abbvie, Vifor, Falk, Laborat\u00f3rios Vitoria, Ferring, Hospira and Biogen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The roles dipeptidyl peptidase 4 (DPP4), aminopeptidase N (APN), and their substrates in autoimmune diseases are being increasingly recognized. However, their significance in inflammatory bowel diseases (IBD) is not entirely understood. This systematic review aims to discuss the pathophysiological processes related to these ectopeptidases while comparing findings from preclinical and clinical settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This review was conducted according to the PRISMA guidelines. We performed a literature search in PubMed, SCOPUS, and Web of Science to identify all reports from inception until February 2020. The search included validated animal models of intestinal inflammation and studies in IBD patients. Quality assessment was performed using SYRCLE\u2019s risk of bias tool and CASP qualitative and cohort checklists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From the 45 included studies, 36 were performed in animal models and 12 in humans (3 reports included both). Overall, the methodological quality of preclinical studies was acceptable. In animal models, DPP4 and APN inhibition significantly improved intestinal inflammation.Glucagon-like peptide (GLP)-1 and GLP-2 analogs and GLP-2-relase-inducing drugs also showed significant benefits in recovery from inflammatory damage. A nonsignificant trend toward disease remission with the GLP-2 analog teduglutide was observed in the sole interventional human study. All human studies reported an inverse correlation between soluble DPP4\/CD26 levels and disease severity, in accordance with the proposal of DPP4 as a biomarker for IBD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of DPP4 inhibitors and analogs of its substrates has clear benefits in the treatment of experimentally induced intestinal inflammation. Further research is warranted to validate their potential diagnostic and therapeutic applications in IBD patients.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izaa324","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:18:50Z","timestamp":1607559530000},"page":"1153-1165","source":"Crossref","is-referenced-by-count":8,"title":["The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.1093","volume":"27","author":[{"given":"Francisco Jorge","family":"Melo","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Unity of Pharmacology and Therapeutics, Faculty of Medicine of the University of Porto, Porto, Portugal"}]},{"given":"Pedro","family":"Pinto-Lopes","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unity of Pharmacology and Therapeutics, Faculty of Medicine of the University of Porto, Porto, Portugal"},{"name":"Department of Internal Medicine, T\u00e2mega e Sousa Hospital Center, Padre Am\u00e9rico Hospital , Penafiel, Portugal"}]},{"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unity of Pharmacology and Therapeutics, Faculty of Medicine of the University of Porto, Porto, Portugal"},{"name":"Department of Gastroenterology, Vila Nova de Gaia\/Espinho Hospital Center , Vila Nova de Gaia, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unity of Pharmacology and Therapeutics, Faculty of Medicine of the University of Porto, Porto, Portugal"},{"name":"Unit of Clinical Pharmacology, S\u00e3o Jo\u00e3o Hospital Center , Porto, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"2022092419282944600_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet."},{"key":"2022092419282944600_CIT0002","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet."},{"key":"2022092419282944600_CIT0003","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/jcp.2003.015214","article-title":"Indeterminate colitis","volume":"57","author":"Guindi","year":"2004","journal-title":"J Clin Pathol."},{"key":"2022092419282944600_CIT0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"2022092419282944600_CIT0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit Rev Clin Lab Sci."},{"key":"2022092419282944600_CIT0006","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dot.1999.35.3.533845","article-title":"Glucagon-like peptide-1: a basis for new approaches to the management of diabetes","volume":"35","author":"Deacon","year":"1999","journal-title":"Drugs Today (Barc)."},{"key":"2022092419282944600_CIT0007","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00125-005-1707-5","article-title":"Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes","volume":"48","author":"Mest","year":"2005","journal-title":"Diabetologia."},{"key":"2022092419282944600_CIT0008","first-page":"673","article-title":"Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases","volume":"19","author":"Cuchacovich","year":"2001","journal-title":"Clin Exp Rheumatol."},{"key":"2022092419282944600_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12781","article-title":"Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system","volume":"185","author":"Klemann","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"2022092419282944600_CIT0010","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1016\/j.febslet.2014.08.029","article-title":"Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells","volume":"588","author":"R\u00f6hrborn","year":"2014","journal-title":"FEBS Lett."},{"key":"2022092419282944600_CIT0011","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1128\/MCB.25.17.7743-7757.2005","article-title":"CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells","volume":"25","author":"Ohnuma","year":"2005","journal-title":"Mol Cell Biol."},{"key":"2022092419282944600_CIT0012","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.4049\/jimmunol.147.8.2514","article-title":"Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes","volume":"147","author":"Torimoto","year":"1991","journal-title":"J Immunol."},{"key":"2022092419282944600_CIT0013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev.iy.12.040194.000505","article-title":"CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development","volume":"12","author":"Trowbridge","year":"1994","journal-title":"Annu Rev Immunol."},{"key":"2022092419282944600_CIT0014","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.4049\/jimmunol.155.10.4630","article-title":"Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule","volume":"155","author":"Mart\u00edn","year":"1995","journal-title":"J Immunol."},{"key":"2022092419282944600_CIT0015","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1073\/pnas.0501050102","article-title":"CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse","volume":"102","author":"Pacheco","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2022092419282944600_CIT0016","doi-asserted-by":"crossref","first-page":"20195","DOI":"10.3390\/ijms160920195","article-title":"Glucagon like Peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-\u03baB (NF-\u03baB) signaling pathway in mice","volume":"16","author":"Zhu","year":"2015","journal-title":"Int J Mol Sci."},{"key":"2022092419282944600_CIT0017","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1210\/jc.2002-021479","article-title":"Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans","volume":"88","author":"Vahl","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"2022092419282944600_CIT0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.peptides.2015.02.007","article-title":"The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine","volume":"67","author":"Pedersen","year":"2015","journal-title":"Peptides."},{"key":"2022092419282944600_CIT0019","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1210\/en.2010-0822","article-title":"Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts","volume":"152","author":"Leen","year":"2011","journal-title":"Endocrinology."},{"key":"2022092419282944600_CIT0020","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1073\/pnas.211278098","article-title":"Modulation of specific intestinal epithelial progenitors by enteric neurons","volume":"98","author":"Bjerknes","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2022092419282944600_CIT0021","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa040","article-title":"GLP-2, EGF, and the intestinal epithelial IGF-1 receptor interactions in the regulation of crypt cell proliferation","volume":"161","author":"Fesler","year":"2020","journal-title":"Endocrinology."},{"key":"2022092419282944600_CIT0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(01)00316-0","article-title":"The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist","volume":"103","author":"Thulesen","year":"2002","journal-title":"Regul Pept."},{"key":"2022092419282944600_CIT0023","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MCG.0000000000000604","article-title":"Safety and efficacy of teduglutide (Gattex) in patients with Crohn\u2019s disease and need for parenteral support due to short bowel syndrome-associated intestinal failure","volume":"51","author":"Kochar","year":"2017","journal-title":"J Clin Gastroenterol."},{"key":"2022092419282944600_CIT0024","doi-asserted-by":"crossref","first-page":"E994","DOI":"10.1152\/ajpendo.00291.2012","article-title":"Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-\u03b3 signaling","volume":"303","author":"de Heuvel","year":"2012","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2022092419282944600_CIT0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gut.19.11.1049","article-title":"Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects","volume":"19","author":"Domschke","year":"1978","journal-title":"Gut."},{"key":"2022092419282944600_CIT0026","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.12688\/f1000research.18039.1","article-title":"Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system","volume":"8","author":"Iwasaki","year":"2019","journal-title":"F1000Research."},{"key":"2022092419282944600_CIT0027","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.4049\/jimmunol.162.8.4685","article-title":"Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation","volume":"162","author":"Delgado","year":"1999","journal-title":"J Immunol."},{"key":"2022092419282944600_CIT0028","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1096\/fj.04-1548fje","article-title":"VIP\/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells","volume":"18","author":"Delgado","year":"2004","journal-title":"Faseb J."},{"key":"2022092419282944600_CIT0029","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0005-2744(80)90202-8","article-title":"Purification and properties of human intestine alanine aminopeptidase","volume":"613","author":"McClellan","year":"1980","journal-title":"Biochim Biophys Acta."},{"key":"2022092419282944600_CIT0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1515\/CCLM.2009.063","article-title":"Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions","volume":"47","author":"Ansorge","year":"2009","journal-title":"Clin Chem Lab Med."},{"key":"2022092419282944600_CIT0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-5793(93)81609-4","article-title":"Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences","volume":"336","author":"Hoffmann","year":"1993","journal-title":"FEBS Lett."},{"key":"2022092419282944600_CIT0032","first-page":"177","article-title":"Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation","volume-title":"Dipeptidyl Aminopeptidases.","author":"Biton"},{"key":"2022092419282944600_CIT0033","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.vascn.2003.12.002","article-title":"Animal models of inflammatory bowel disease","volume":"50","author":"Jurjus","year":"2004","journal-title":"J Pharmacol Toxicol Methods."},{"key":"2022092419282944600_CIT0034","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med."},{"key":"2022092419282944600_CIT0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol."},{"volume-title":"CASP Qualitative Checklist.","author":"Critical Appraisal Skills Programme (2019)","key":"2022092419282944600_CIT0036"},{"volume-title":"CASP Cohort Checklist.","author":"Critical Appraisal Skills Programme (2019)","key":"2022092419282944600_CIT0037"},{"key":"2022092419282944600_CIT0038","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1053\/jpsu.2000.6861","article-title":"Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2","volume":"35","author":"Alavi","year":"2000","journal-title":"J Pediatr Surg."},{"key":"2022092419282944600_CIT0039","doi-asserted-by":"crossref","first-page":"e50630","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn\u2019s disease model","volume":"7","author":"Alters","year":"2012","journal-title":"Plos One."},{"key":"2022092419282944600_CIT0040","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nano.2016.08.004","article-title":"GLP-1 nanomedicine alleviates gut inflammation","volume":"13","author":"Anbazhagan","year":"2017","journal-title":"Nanomedicine."},{"key":"2022092419282944600_CIT0041","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jpedsurg.2003.11.024","article-title":"Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease","volume":"39","author":"Arthur","year":"2004","journal-title":"J Pediatr Surg."},{"key":"2022092419282944600_CIT0042","first-page":"1699","article-title":"The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis","volume":"25","author":"Ban","year":"2011","journal-title":"Oncol Rep."},{"key":"2022092419282944600_CIT0043","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.intimp.2006.09.014","article-title":"Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV\/CD26) and Aminopeptidase N (APN\/ CD13)\u2013a novel approach for the treatment of inflammatory bowel disease","volume":"6","author":"Bank","year":"2006","journal-title":"Int Immunopharmacol."},{"key":"2022092419282944600_CIT0044","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/jcb.23261","article-title":"Neuroimmunomodulative properties of dipeptidyl peptidase IV\/CD26 in a TNBS-induced model of colitis in mice","volume":"112","author":"Baticic","year":"2011","journal-title":"J Cell Biochem."},{"key":"2022092419282944600_CIT0045","first-page":"E937","article-title":"Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis","volume":"277","author":"Boushey","year":"1999","journal-title":"Am J Physiol."},{"key":"2022092419282944600_CIT0046","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1002\/jcb.26867","article-title":"The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn\u2019s disease","volume":"119","author":"Buljevic","year":"2018","journal-title":"J Cell Biochem."},{"key":"2022092419282944600_CIT0047","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13105-016-0491-7","article-title":"Influence of CD26\/dipeptidyl peptidase IV deficiency on immunophenotypic changes during colitis development and resolution","volume":"72","author":"Detel","year":"2016","journal-title":"J Physiol Biochem."},{"key":"2022092419282944600_CIT0048","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1113\/expphysiol.2011.061143","article-title":"Development and resolution of colitis in mice with target deletion of dipeptidyl peptidase IV","volume":"97","author":"Detel","year":"2012","journal-title":"Exp Physiol."},{"key":"2022092419282944600_CIT0049","first-page":"G79","article-title":"Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis","volume":"276","author":"Drucker","year":"1999","journal-title":"Am J Physiol."},{"key":"2022092419282944600_CIT0050","doi-asserted-by":"crossref","first-page":"G274","DOI":"10.1152\/ajpgi.00389.2012","article-title":"Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration","volume":"307","author":"El-Jamal","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"2022092419282944600_CIT0051","doi-asserted-by":"crossref","first-page":"140","DOI":"10.9734\/BJPR\/2015\/18241","article-title":"Effect of different doses of sitagliptin in treatment of experimentally induced colitis in mice","volume":"7","author":"Elkatary","year":"2015","journal-title":"Br J Pharm Res."},{"key":"2022092419282944600_CIT0052","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3164\/jcbn.14-111","article-title":"Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration","volume":"56","author":"Fujiwara","year":"2015","journal-title":"J Clin Biochem Nutr."},{"key":"2022092419282944600_CIT0053","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jcp.20333","article-title":"Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV","volume":"204","author":"Geier","year":"2005","journal-title":"J Cell Physiol."},{"key":"2022092419282944600_CIT0054","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bcp.2018.07.027","article-title":"The protective and anti-inflammatory effects of a modified glucagon-like peptide-2 dimer in inflammatory bowel disease","volume":"155","author":"Gu","year":"2018","journal-title":"Biochem Pharmacol."},{"key":"2022092419282944600_CIT0055","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1007\/s10620-013-3001-6","article-title":"Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats","volume":"59","author":"Inoue","year":"2014","journal-title":"Dig Dis Sci."},{"key":"2022092419282944600_CIT0056","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1271\/bbb.130105","article-title":"Contribution of dipeptidyl peptidase IV to the severity of dextran sulfate sodium-induced colitis in the early phase","volume":"77","author":"Iwaya","year":"2013","journal-title":"Biosci Biotechnol Biochem."},{"key":"2022092419282944600_CIT0057","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.4155\/fmc-2016-0156","article-title":"Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis","volume":"8","author":"Kamysz","year":"2016","journal-title":"Future Med Chem."},{"key":"2022092419282944600_CIT0058","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jphs.2019.05.003","article-title":"G protein-coupled receptor 40 activation ameliorates dextran sulfate sodium-induced colitis in mice via the upregulation of glucagon-likepeptide-2","volume":"140","author":"Kato","year":"2019","journal-title":"J Pharmacol Sci."},{"key":"2022092419282944600_CIT0059","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1210\/en.2011-1954","article-title":"Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis","volume":"153","author":"Lee","year":"2012","journal-title":"Endocrinology."},{"key":"2022092419282944600_CIT0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/jpet.103.051771","article-title":"Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis","volume":"306","author":"L\u2019Heureux","year":"2003","journal-title":"J Pharmacol Exp Ther."},{"key":"2022092419282944600_CIT0061","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3109\/00365521.2013.832366","article-title":"Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis","volume":"48","author":"Mimura","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"2022092419282944600_CIT0062","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12876-017-0593-x","article-title":"Therapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male rats","volume":"17","author":"Qi","year":"2017","journal-title":"BMC Gastroenterol."},{"key":"2022092419282944600_CIT0063","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.peptides.2013.11.012","article-title":"Purified PEGylated porcine glucagon-like peptide-2 reduces the severity of colonic injury in a murine model of experimental colitis","volume":"52","author":"Qi","year":"2014","journal-title":"Peptides."},{"key":"2022092419282944600_CIT0064","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/jgh.12740","article-title":"The effects of a TGR5 agonist and a dipeptidyl peptidase IV inhibitor on dextran sulfate sodium-induced colitis in mice","volume":"30","author":"Sakanaka","year":"2015","journal-title":"J Gastroenterol Hepatol."},{"key":"2022092419282944600_CIT0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.peptides.2018.08.011","article-title":"Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis","volume":"108","author":"Salaga","year":"2018","journal-title":"Peptides."},{"key":"2022092419282944600_CIT0066","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjx043","article-title":"Systemic administration of sialorphin attenuates experimental colitis in mice via interaction with mu and kappa opioid receptors","volume":"11","author":"Salaga","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2022092419282944600_CIT0067","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/jpet.117.242586","article-title":"New peptide inhibitor of dipeptidyl Peptidase IV, EMDB-1 extends the half-life of GLP-2 and attenuates colitis in mice after topical administration","volume":"363","author":"Salaga","year":"2017","journal-title":"J Pharmacol Exp Ther."},{"key":"2022092419282944600_CIT0068","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/003655200750023796","article-title":"Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells","volume":"35","author":"Schmidt","year":"2000","journal-title":"Scand J Gastroenterol."},{"key":"2022092419282944600_CIT0069","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/02652048.2015.1065923","article-title":"Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model","volume":"32","author":"Wu","year":"2015","journal-title":"J Microencapsul."},{"key":"2022092419282944600_CIT0070","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/acs.jmedchem.7b00768","article-title":"Stapled, long-acting glucagon-like peptide 2 analog with efficacy in dextran sodium sulfate induced mouse colitis models","volume":"61","author":"Yang","year":"2018","journal-title":"J Med Chem."},{"key":"2022092419282944600_CIT0071","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.2741\/3193","article-title":"Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice","volume":"13","author":"Yazbeck","year":"2008","journal-title":"Front Biosci."},{"key":"2022092419282944600_CIT0072","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/jcp.22682","article-title":"Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis","volume":"226","author":"Yazbeck","year":"2011","journal-title":"J Cell Physiol."},{"key":"2022092419282944600_CIT0073","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ibd.21241","article-title":"Dipeptidyl peptidase expression during experimental colitis in mice","volume":"16","author":"Yazbeck","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282944600_CIT0074","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/ibd.21117","article-title":"Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn\u2019s disease","volume":"16","author":"Buchman","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282944600_CIT0075","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5217\/ir.2017.15.3.352","article-title":"Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn\u2019s disease","volume":"15","author":"Magro","year":"2017","journal-title":"Intest Res."},{"key":"2022092419282944600_CIT0076","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.regpep.2012.04.006","article-title":"Dipeptidyl peptidase-4 expression is reduced in Crohn\u2019s disease","volume":"177","author":"Moran","year":"2012","journal-title":"Regul Pept."},{"key":"2022092419282944600_CIT0077","first-page":"1","article-title":"Serum dipeptidyl peptidase 4: a predictor of disease activity and prognosis in inflammatory bowel disease","volume":"XX","author":"Pinto-Lopes","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022092419282944600_CIT0078","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00042737-200502000-00012","article-title":"Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY","volume":"17","author":"Schmidt","year":"2005","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2022092419282944600_CIT0079","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajpath.2014.09.010","article-title":"Tumor necrosis factor \u03b1 decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease","volume":"185","author":"Tsukahara","year":"2015","journal-title":"Am J Pathol."},{"key":"2022092419282944600_CIT0080","first-page":"427","article-title":"Clinical relevance of the serum dipeptidyl peptidase IV (DPP IV\/CD26) activity in adult patients with Crohn\u2019s disease and Ulcerative colitis","volume":"78","author":"Varljen","year":"2005","journal-title":"Croat Chem Acta."},{"key":"2022092419282944600_CIT0081","doi-asserted-by":"crossref","first-page":"R1057","DOI":"10.1152\/ajpregu.2000.278.4.R1057","article-title":"Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease","volume":"278","author":"Xiao","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"2022092419282944600_CIT0082","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/003655201750422675","article-title":"Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease","volume":"36","author":"Hildebrandt","year":"2001","journal-title":"Scand J Gastroenterol."},{"key":"2022092419282944600_CIT0083","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1152\/physrev.00041.2018","article-title":"Free fatty acid receptors in health and disease","volume":"100","author":"Kimura","year":"2020","journal-title":"Physiol Rev."},{"key":"2022092419282944600_CIT0084","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3389\/fphys.2016.00646","article-title":"TGR5, not only a metabolic regulator","volume":"7","author":"Guo","year":"2016","journal-title":"Front Physiol."},{"key":"2022092419282944600_CIT0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.tips.2017.06.006","article-title":"FFA4\/GPR120: pharmacology and therapeutic opportunities","volume":"38","author":"Milligan","year":"2017","journal-title":"Trends Pharmacol Sci."},{"key":"2022092419282944600_CIT0086","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V98.13.3554","article-title":"Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties","volume":"98","author":"Proost","year":"2001","journal-title":"Blood."},{"key":"2022092419282944600_CIT0087","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood.V96.5.1674","article-title":"Cleavage by CD26\/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist","volume":"96","author":"Proost","year":"2000","journal-title":"Blood."},{"key":"2022092419282944600_CIT0088","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-0115(96)00104-8","article-title":"Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors","volume":"67","author":"Grandt","year":"1996","journal-title":"Regul Pept."},{"key":"2022092419282944600_CIT0089","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.regpep.2006.07.003","article-title":"DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells","volume":"137","author":"Masur","year":"2006","journal-title":"Regul Pept."},{"key":"2022092419282944600_CIT0090","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1060028019827852","article-title":"Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis","volume":"53","author":"Radel","year":"2019","journal-title":"Ann Pharmacother."},{"key":"2022092419282944600_CIT0091","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ni.3201","article-title":"Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy","volume":"16","author":"Barreira da Silva","year":"2015","journal-title":"Nat Immunol."},{"key":"2022092419282944600_CIT0092","first-page":"123","article-title":"Synergistic action of DPIV and APN in the regulation of T cell function","volume-title":"Dipeptidyl Aminopeptidases in Health and Disease.","author":"Lendeckel"},{"key":"2022092419282944600_CIT0093","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/0-387-32824-6_15","article-title":"Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis","volume":"575","author":"Bank","year":"2006","journal-title":"Adv Exp Med Biol."},{"key":"2022092419282944600_CIT0094","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med."},{"key":"2022092419282944600_CIT0095","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.4049\/jimmunol.1103801","article-title":"Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26)","volume":"188","author":"Bengsch","year":"2012","journal-title":"J Immunol."},{"key":"2022092419282944600_CIT0096","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3389\/fmicb.2018.01900","article-title":"The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health","volume":"9","author":"Olivares","year":"2018","journal-title":"Front Microbiol."},{"key":"2022092419282944600_CIT0097","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcjd.2019.05.008","article-title":"Metformin and dipeptidyl peptidase-4 inhibitor differentially modulate the intestinal microbiota and plasma metabolome of metabolically dysfunctional mice","volume":"44","author":"Ryan","year":"2020","journal-title":"Can J Diabetes."},{"key":"2022092419282944600_CIT0098","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2019.02.015","article-title":"CD26\/DPP4 - a potential biomarker and target for cancer therapy","volume":"198","author":"Enz","year":"2019","journal-title":"Pharmacol Ther."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/7\/1153\/45992771\/izaa324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/27\/7\/1153\/45992771\/izaa324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:42:25Z","timestamp":1697319745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/27\/7\/1153\/6028655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":98,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,9]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa324","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2020,12,9]]}}}